|Bid||143.41 x 1000|
|Ask||148.08 x 800|
|Day's Range||145.13 - 148.48|
|52 Week Range||90.61 - 156.16|
|Beta (3Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||160.67|
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Kevin Sayer, chairman, president and CEO of Dexcom Inc. The trend-following Moving Average Convergence Divergence (MACD) oscillator just moved above the zero line for an outright buy signal on this time frame.
Dexcom Inc NASDAQ/NGS:DXCMView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for DXCM with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold DXCM had net inflows of $1.27 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
DexCom, Inc. (DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users. Dexcom and Companion Medical are working together to develop a seamless data transfer of both insulin and glucose information.
While DexCom, Inc. (NASDAQ:DXCM) shareholders are probably generally happy, the stock hasn't had particularly good run...
DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.
DexCom (DXCM) delivered earnings and revenue surprises of 70.59% and 13.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 5 cents per share. The results exceeded Wall Street expectations. The average estimate ...
DexCom (NASDAQ: DXCM ) releases its next round of earnings this Wednesday, May 1. Get the latest predictions in Benzinga's essential guide to the company's first-quarter earnings report. Earnings and Revenue ...
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he wouldn't buy Sarepta Therapeutics Inc (NASDAQ: SRPT ) because it's a one-drug company. Cramer wouldn't buy The Blackstone Group L.P. ...
The stock market is being flooded with new initial public offerings and many of the best performers in the 2019 class aren't worth chasing at current levels, CNBC's Jim Cramer said Thursday. Cramer likes to see stock prices run higher, but the deluge of frothy IPOs is not a good sign in his eyes. Cramer said his fear is that the deals will become less rewarding, leaving investors burned and turning against stocks as an asset class.
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. HCA Holdings Inc. HCA : "HCA is down very big, it's part of this anti health care market, but I believe when Intel INTC slashes its forecast because of the decline in data center, that money's gonna roll back into HC, which we call it health care, and the natural one it will roll back into is HCA. Tractor Supply Co. TSCO : "Did you see that stock break out in the last few days?